PubRank

Ronald D Alvarez

Author PubWeight™ 126.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003 7.35
2 Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003 3.67
3 Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2011 2.03
4 Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol 2002 1.74
5 Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002 1.74
6 Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 2004 1.70
7 In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst 2002 1.61
8 Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol 2008 1.54
9 Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol 2014 1.46
10 A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 2004 1.44
11 Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003 1.43
12 Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist 2006 1.40
13 Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 2003 1.40
14 Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol Oncol 2002 1.38
15 Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008 1.29
16 Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002 1.28
17 Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 2013 1.27
18 A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010 1.21
19 Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study. Am J Obstet Gynecol 2004 1.17
20 Epithelial ovarian cancer. J Natl Compr Canc Netw 2011 1.16
21 Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002 1.15
22 Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009 1.14
23 Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003 1.14
24 Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol 2009 1.14
25 Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther 2012 1.13
26 Ovarian cancer, version 2.2013. J Natl Compr Canc Netw 2013 1.13
27 Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther 2004 1.12
28 A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol 2013 1.10
29 Ovarian cancer, version 3.2012. J Natl Compr Canc Netw 2012 1.08
30 Gene therapy for ovarian cancer. Curr Oncol Rep 2006 1.08
31 Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016 1.06
32 Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2008 1.04
33 Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 2008 1.04
34 A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res 2012 1.04
35 Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res 2011 1.03
36 A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma. Gynecol Oncol 2011 1.02
37 DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007 1.02
38 A prospective evaluation of "see and treat" in women with HSIL Pap smear results: is this an appropriate strategy? J Low Genit Tract Dis 2005 1.02
39 A higher degree of methylation of the HPV 16 E6 gene is associated with a lower likelihood of being diagnosed with cervical intraepithelial neoplasia. Cancer 2010 1.01
40 Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci 2008 1.01
41 Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 2003 0.99
42 Lower risk of cervical intraepithelial neoplasia in women with high plasma folate and sufficient vitamin B12 in the post-folic acid fortification era. Cancer Prev Res (Phila) 2009 0.99
43 Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 2007 0.98
44 Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. Int J Oncol 2005 0.97
45 Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 2005 0.96
46 Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2012 0.96
47 The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 2003 0.95
48 Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol Oncol 2003 0.94
49 Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosis. Virology 2004 0.94
50 Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother 2013 0.94
51 Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 2008 0.93
52 Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2007 0.93
53 Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2003 0.93
54 A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 2008 0.93
55 Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 2007 0.93
56 Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane. J Oncol 2013 0.92
57 Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol Oncol 2006 0.92
58 Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol 2009 0.92
59 Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 2013 0.92
60 Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. Int J Oncol 2008 0.91
61 Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol 2010 0.91
62 Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther 2002 0.91
63 Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J Gene Med 2004 0.91
64 A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice. Mol Ther 2012 0.90
65 Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer. Mol Imaging 2009 0.90
66 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008 0.90
67 Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp Cell Res 2013 0.90
68 Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell Biosci 2014 0.90
69 Single-chain antibodies: A therapeutic modality for cancer gene therapy (review). Int J Oncol 2004 0.89
70 Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol Oncol 2008 0.89
71 Targeted gene therapy for ovarian cancer. Curr Gene Ther 2005 0.89
72 Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol 2005 0.89
73 A higher degree of LINE-1 methylation in peripheral blood mononuclear cells, a one-carbon nutrient related epigenetic alteration, is associated with a lower risk of developing cervical intraepithelial neoplasia. Nutrition 2011 0.89
74 Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J Reprod Med 2004 0.89
75 Gene transfer to cervical cancer with fiber-modified adenoviruses. Int J Cancer 2004 0.88
76 Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin Cancer Res 2009 0.87
77 Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol 2013 0.87
78 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecol Oncol 2007 0.87
79 A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway. Clin Cancer Res 2007 0.87
80 Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum Gene Ther 2004 0.87
81 High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virus. J Low Genit Tract Dis 2004 0.87
82 Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2013 0.86
83 Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol 2006 0.86
84 Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecol Oncol 2005 0.85
85 A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients. Hum Gene Ther 2011 0.85
86 Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma. Gynecol Oncol 2004 0.84
87 Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol 2007 0.84
88 Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature. Expert Opin Biol Ther 2011 0.84
89 Circumventing recombination events encountered with production of a clinical-grade adenoviral vector with a double-expression cassette. Mol Pharmacol 2006 0.84
90 Adenoviruses in oncology: a viable option? BioDrugs 2002 0.83
91 LUMA cervical imaging system. Expert Rev Med Devices 2007 0.83
92 Advancements in adenoviral based virotherapy for ovarian cancer. Adv Drug Deliv Rev 2009 0.83
93 A lower degree of PBMC L1 methylation is associated with excess body weight and higher HOMA-IR in the presence of lower concentrations of plasma folate. PLoS One 2013 0.83
94 The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy. Gynecol Oncol 2004 0.82
95 Conditionally replicative adenoviruses for ovarian cancer therapy. Mol Cancer Ther 2002 0.82
96 Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther 2003 0.82
97 Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 2004 0.82
98 Molecular/genetic therapies in ovarian cancer: future opportunities and challenges. Clin Obstet Gynecol 2012 0.81
99 A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008 0.80
100 Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer. Arch Gynecol Obstet 2010 0.80
101 The impact of aborted radical hysterectomy in patients with cervical carcinoma. Gynecol Oncol 2004 0.80
102 Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. Gynecol Oncol 2005 0.80
103 A dietary pattern associated with LINE-1 methylation alters the risk of developing cervical intraepithelial neoplasia. Cancer Prev Res (Phila) 2012 0.80
104 Advances in the treatment of gynecologic malignancies. Part 1: Cancers of the cervix and vulva. Oncology (Williston Park) 2002 0.80
105 Transcriptional blocks limit adenoviral replication in primary ovarian tumor. Clin Cancer Res 2004 0.79
106 Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. J Mol Med (Berl) 2013 0.79
107 An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol 2009 0.79
108 The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy. Int J Gynecol Cancer 2013 0.79
109 A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 2006 0.78
110 Human papillomavirus: what every provider should know. Am J Obstet Gynecol 2012 0.78
111 Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006 0.78
112 Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study. J Reprod Med 2014 0.78
113 Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol 2008 0.77
114 Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. Int J Gynecol Cancer 2009 0.77
115 Ovarian cancer clinical practice guidelines. J Natl Compr Canc Netw 2004 0.77
116 Monitoring of biodistribution and persistence of conditionally replicative adenovirus in a murine model of ovarian cancer using capsid-incorporated mCherry and expression of human somatostatin receptor subtype 2 gene. Mol Imaging 2014 0.77
117 Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Cancer 2003 0.77
118 Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies. Gynecol Oncol 2011 0.77
119 Gene therapy. Cancer Treat Res 2002 0.76
120 Advances in the treatment of gynecologic malignancies. Part 2: Cancers of the uterine corpus and ovary. Oncology (Williston Park) 2002 0.76
121 Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol 2016 0.75
122 Complications of indwelling venous access devices in patients with gynecologic malignancies. Gynecol Oncol 2003 0.75
123 Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project. Int J Gynecol Cancer 2015 0.75
124 Unilateral cervical cancer in a patient with cervix duplex. Gynecol Oncol 2006 0.75
125 Evolving Paradigms in Research and Care in Ovarian Cancers. Obstet Gynecol 2016 0.75
126 New advances in vaccine technology and improved cervical cancer prevention. Obstet Gynecol 2007 0.75
127 Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer. Gynecol Oncol 2006 0.75
128 Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy. Gynecol Oncol 2006 0.75
129 Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy. Gynecol Oncol 2012 0.75
130 Integrating the Gynecologic Oncology Group and Gynecologic Cancer SPOREs--a square peg in a round hole or fits like a glove? Gynecol Oncol 2007 0.75
131 Inflammatory pseudotumor of pelvic lymph nodes. Obstet Gynecol 2006 0.75
132 Gene therapy for ovarian cancer: progress and potential. Hematol Oncol Clin North Am 2003 0.75
133 Novel therapies for recurrent ovarian cancer management. Expert Rev Anticancer Ther 2004 0.75
134 Using a multivariate index assay to assess malignancy in a pelvic mass. Obstet Gynecol 2012 0.75
135 Novel methods to treat and prevent human papillomavirus infection. Expert Rev Anti Infect Ther 2006 0.75